Gunggung dhuwit awis saben saham Armata Pharmaceuticals (ARMP)

Simbol lan logo merek Armata (ARMP)

Armata Pharmaceuticals (ARMP) develops treatments against resistant bacteria in US laboratories. The GURU.Markets platform tracks the cash per share trend, where 0.49 indicates the value of this parameter. High demand is driven by a unique platform of targeted phages that eliminate infections. Current viability relies on external capital and scientific potential until clinical trials are completed.

Dhuwit awis saben saham: Armata Pharmaceuticals, Inc. (ARMP) kanggo 04.07.2022 - 20.11.2026

Rincian metrik komprehensif lan analitis armatapharma.com (ARMP)

- rega lan prakiraan konsensus rega:
- data dhuwit lan arus kas:
Analisis umum perusahaan:Armata - ARMP
Produk dadi Armata Pharmaceuticals

For Armata Pharmaceuticals (ARMP), which is developing innovative phage therapies against superbugs, this metric reflects the actual amount of liquidity per share net of all liabilities. By analyzing the quarterly trend of cash per share, an investor assesses the biotech brand's financial resilience against cash flow gaps, where growth in this metric confirms the availability of resources to complete costly clinical trials.